Blood Reviews
Volume 22, Issue 4 , Pages 211-219 , July 2008

New prognostic markers in chronic lymphocytic leukemia

References 

  1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
  2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206
  3. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984;64:642–648
  4. Gray JL, Jacobs A, Block M. Bone marrow and peripheral blood lymphocytosis in the prognosis of chronic lymphocytic leukemia. Cancer. 1974;33:1169–1178
  5. Han T, Barcos M, Emrich L, et al. Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia: correlations with clinical, immunologic, phenotypic, and cytogenetic data. J Clin Oncol. 1984;2:562–570
  6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood. In press.
  7. Muntañola A, Bosch F, Arguis P, et al. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol. 2007;25:1576–1580
  8. Eichhorst BF, Busch R, Hopfinger G, et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891
  9. Blum KA, Young D, Broering S, et al. Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria. J Clin Oncol. 2007;25:5624–5629
  10. Bruzzi JF, Macapinlac H, Tsimberidou AM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006;47:1267–1273
  11. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352:804–815
  12. Messmer BT, Messmer D, Allen SL, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005;115:755–764
  13. Orfao A, Ciudad J, González M, et al. Prognostic value of S-phase white blood cell count in B-cell chronic lymphocytic leukemia. Leukemia. 1992;6:47–51
  14. Damle RN, Batliwalla FM, Ghiotto F, et al. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood. 2004;103:375–382
  15. Roos G, Krober A, Grabowski P, et al. Short telomeres are associated with genetic complexity, high risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood. Prepublished on November 28, 2007, as 10.1182/blood-2007-05-092759.
  16. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62:567–575
  17. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica. 2005;90:391–399
  18. Seiler T, Döhner H, Stingelbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncology. 2006;33:186–194
  19. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood. 1999;93:1732–1737
  20. Knauf WU, Ehlers B, Mohr B, et al. Prognostic impact of the serum levels of soluble CD23 in B-cell chronic lymphocytic leukemia. Blood. 1997;89:4241–4242
  21. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukaemia. J Clin Oncol. 2005;23:1–8
  22. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;223:40–47
  23. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;107:605–610
  24. Pepper C, Ward R, Lin TT, et al. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia. 2007;21:687–696
  25. Martinelli S, Maffei R, Castelli I, et al. G. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis. Leuk Res. Prepublished on October 24, 2007 as 10.1016/j.leukres.2007.09.002.
  26. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414–1418
  27. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002;100:3344–3351
  28. Molica S, Cutrona G, Vitelli G, et al. Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res. 2007;31:1575–1578
  29. Calin GA, Ferracin M, Cimmino A, et al. A Micro RNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005;353:1793–1801
  30. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007;20:425–437
  31. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916
  32. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370:230–239
  33. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006;24:4634–4641
  34. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica. 2007;92:1242–1245
  35. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–751
  36. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108:3152–3160
  37. Van Den Neste E, Robin V, Francart J, et al. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. Leukemia. 2007;21:1715–1722
  38. Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res. 2006;66:11590–11593
  39. Herling M, Patel KA, Khalili J, et al. TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006;20:280–285
  40. Buhl AM, Jurlander J, Jorgensen FS, et al. Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. Blood. 2006;107:2904–2911
  41. Josefsson P, Geisler CH, Leffers H, et al. CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood. 2007;109:4973–4979
  42. Matthews C, Catherwood MA, Larkin AM, Clynes M, Morris TC, Alexander HD. MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47:2308–2313
  43. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
  44. Damle RN, Wasil T, Fais F, et al. Ig VH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
  45. Krober A, Seiler T, Benner A, et al. IgVH mutation status, CD38 expression level, genomic aberrations, and prognosis in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416
  46. Hamblin TJ, Davis ZA, Oscier DG. Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. Br J Haematol. Prepublished on December 5, 2007 as 10.1111/j.1365-2141.2007.06928.x.
  47. Vasconcelos Y, Davi F, Levy V, et al. Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003;21:3928–3932
  48. Tobin G, Rosenquist R. Prognostic usage of V(H) gene mutation status and its surrogates markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol. 2005;22:217–228
  49. Thorsélius M, Kröber A, Murray F, et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood. 2006;107:2889–2894
  50. Tschumper RC, Geyer SM, Campbell ME, et al. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest. 2008;118:306–315
  51. Ghia P, Stamatopoulos K, Belessi C, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia [editorial]. Leukemia. 2007;21:1–3
  52. Boonstra JG, van Lom K, Langerak AW, et al. CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. Cytometry B Clin Cytom. 2006;70:136–141
  53. Zucchetto A, Sonego P, Degan M, et al. Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukaemia (B-CLL): Identification of markers with prognostic relevance. J Immunol Methods. 2005;305:20–32
  54. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood. 2008;111:865–873
  55. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647
  56. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775
  57. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944–4951
  58. Carreras J, Villamor N, Colomo L, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol. 2005;205:507–513
  59. Catherwood MA, Matthews C, Niblock R, Dobbin E, Morris TC, Denis Alexander H. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2006;76:294–298
  60. Roullet M, Sargent R, Pasha T, et al. ZAP70 Expression Assessed by Immunohistochemistry on Peripheral Blood: A Simple Prognostic Assay for Patients With Chronic Lymphocytic Leukemia. Appl Immunohistochem Mol Morphol. 2007;15:471–476
  61. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105–111
  62. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893–901
  63. Del Principe MI, Del Poeta G, Buccisano F, et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood. 2006;108:853–861
  64. Bosch F, Muntañola A, Giné E, et al. Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2006;70:214–217
  65. Krober A, Bloehdom J, Hafner S, et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol. 2006;24:969–975
  66. Villamor N, Crespo M, Bosch F, et al. ZAP-70 expression remains stable during the course of chronic lymphocytic leukemia [abstract]. Leuk Lymphoma 2005;46 (suppl 1):S43.Abstract 19.
  67. Poulain S, Benard C, Daudignon A, Le Baron F, Morel P, Duthilleul P. Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia?. Leuk Lymphoma. 2007;48:1219–1221
  68. Del Diudice I, Morilla A, Osuji N, et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer. 2005;104:2124–2132
  69. Schroers R, Griesinger F, Trümper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:750–758
  70. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol. 2006;17:683–690
  71. Heintel D, Kroemer E, Kienle D, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IgVH gene status and unfavorable cytogenetic aberrations in patients with chronic lymphocytic leukemia. Leukemia. 2004;18:756–762
  72. Nückel H, Hüttmann A, Klein-Hitpass L, et al. Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2006;47:1053–1061
  73. van´t Veer MB, Brooijmans AM, Langerak AW, et al. The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica. 2006;91:56–63
  74. Li FJ, Li Y, Shakhmatov MA, et al. FCRL2 Expression Is Predictive of IgVH Mutation Status and Clinical Progression in Chronic Lymphocytic Leukemia [abstract]. Blood 2007;110:Abstract 488.
  75. Bosch F, Ferrer A, López-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol. 2002;119:976–984
  76. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after therapy with alemtuzumab is associated with prolonged survival. J Clin Oncol. 2005;23:2971–2979
  77. Bosch F, Ferrer A, Villamor N, et al. Fludarabine, Cyclophosphamide and Mitoxantrone as Intial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication. Clin Cancer Res. 2008;14:155–161
  78. Montserrat E. Treatment of chronic lymphocytic leukemia: achieving minimal residual disease – negative status as a goal [editorial]. J Clin Oncol. 2005;23:2884–2885
  79. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956–964
  80. Byrd JC, Gribben JG, Peterson BL, et al. Selected high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006;24:437–443
  81. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time to treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol. 2006;13:266–272
  82. Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25:799–804
  83. Hauswirth AW, Jager U. Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukaemia. Haematologica. 2008;93:14–19
  84. Lin KI, Tam CS, Abruzzo LV, et al. IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy [abstract]. Blood 2007;110:Abstract 753.
  85. Dreger P, Corradini P, Kimby E, et al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12–17

PII: S0268-960X(08)00021-0

doi: 10.1016/j.blre.2008.03.003

Blood Reviews
Volume 22, Issue 4 , Pages 211-219 , July 2008

Article Tools

* Image Usage & Resolution